Prostate Cancer BC Video Library

Prostate Cancer BC and its support initiative, Prostate Cancer Support Canada, host monthly Coast to Coast meetings featuring prostate cancer experts on different topics. May 2022's meeting featured Dr. Christopher Wallis speaking on prostate cancer treatment regret and decisions. Christopher J.D. Wallis is a Urologic Oncologist at the University of Toronto and Mount Sinai Hospital/University Health Network. He obtained his Doctor of Medicine from the University of British Columbia and his Doctor of Philosophy in Clinical Epidemiology & Health Care Research from the Institute of Health Policy, Management & Evaluation at the University of Toronto and completed his clinical residency in Urology at the University of Toronto affiliated hospitals and his Society of Urologic Oncology accredited fellowship training at Vanderbilt University Medical Center. His research focuses on leveraging a variety of epidemiologic techniques to understand the interaction between processes of care and patient outcomes, with a particular focus on patients with cancer and those undergoing surgery. Recently, his work has focused heavily on understanding the interplay between physician characteristics and patients’ operative outcomes. For more information on Prostate Cancer Support Canada, Prostate Cancer Foundation BC's support initiative, please visit: www.prostatecancersupport.ca The views, information, and opinions expressed in this video are those of the individuals involved and do not necessarily reflect the official policy or position of the Prostate Cancer Foundation BC or its employees. PCFBC is not responsible and does not verify for accuracy any of the information contained in the videos available for watching on this site. The primary purpose of these videos is to educate and inform, but these videos do not constitute, or replace, medical or other professional advice.

The 2022 Prostate Cancer Virtual Conference presented by Prostate Cancer Foundation BC and its support initiative, Prostate Cancer Support Canada, took place over the weekend of September 17th and 18th. The second day of the Conference, 'Prostate Cancer Realities,' focussed on what prostate cancer patients need to know while on their prostate cancer journeys. Dr. Juanita Crook, Radiation Oncologist, and Dr. Neil Dwyer, Urologist, answer the most asked questions they receive from prostate cancer patients. For more information on Prostate Cancer Foundation BC, please visit prostatecancerbc.ca For more information on Prostate Cancer Support Canada, Prostate Cancer Foundation BC's support initiative, please visit: www.prostatecancersupport.ca The views, information, and opinions expressed in this video are those of the individuals involved and do not necessarily reflect the official policy or position of the Prostate Cancer Foundation BC or its employees. PCFBC is not responsible and does not verify for accuracy any of the information contained in the videos available for watching on this site. The primary purpose of these videos is to educate and inform, but these videos do not constitute, or replace, medical or other professional advice.

This video is a recording of Prostate Cancer BC and Prostate Cancer Support Canada's Nationwide Active Surveillance Support Group meeting held over Zoom. --- In honour of Prostate Cancer Awareness Month, Dr. Laurence Klotz, MD, FCRPC, and pioneer of Active Surveillance will be joining us for our September meeting. Don't miss out on this opportunity to chat with Canada's leading expert in Active Surveillance. This new nationwide Active Surveillance support group aims to bring together prostate cancer patients and advocates who will empower men newly diagnosed with low-risk and intermediate prostate cancer by providing them with the latest information to help them make informed decisions with their physicians regarding approaches to active surveillance. Go to http://prostatecancersupport.ca/ to find out more. --- About Laurence Klotz, CM, MD, FRCSC: Dr. Klotz is a widely published uro-oncologist (504 peer review publications, 6 books). His basic research interests have included research in the role of micronutrients and diet in prostate cancer prevention, and translational research in biomarkers and imaging. His research lab has been active for 30 years, producing several patents and a biotech company. His clinical research interests have been in the areas of active surveillance, image guided therapy, molecular biomarkers, and androgen receptor targeted therapy. He has led numerous randomized trials in prostate cancer. Active surveillance was a concept pioneered under Dr. Klotz’s leadership. He led the team at Sunnybrook who was the first to implement an approach to patients with low risk prostate cancer based on conservative management, with selective intervention for those patients who were diagnosed as higher risk over time. He coined the term ‘active surveillance’, and was responsible for promoting its acceptance by urological and radiation oncology communities worldwide. His drive to reduce the overtreatment, morbidity, and mortality of prostate cancer has led to over a hundred papers on this subject alone and numerous national and international invitations as a guest lecturer and visiting professor. --- The views, information, and opinions expressed in this video are those of the individuals involved and do not necessarily reflect the official policy or position of the Prostate Cancer Foundation BC or its employees. PCFBC is not responsible and does not verify for accuracy any of the information contained in the videos available for watching on this site. The primary purpose of these videos is to educate and inform, but these videos do not constitute, or replace, medical or other professional advice.

The 2022 Prostate Cancer Virtual Conference presented by Prostate Cancer Foundation BC and its support initiative, Prostate Cancer Support Canada, took place over the weekend of September 17th and 18th. The second day of the Conference, 'Prostate Cancer Realities,' focussed on what prostate cancer patients need to know while on their prostate cancer journeys. This video shows Dr. Richard Wassersug, research scientist, speaking on safely researching prostate cancer on the internet and how to determine if websites are reputable. For more information on Prostate Cancer Foundation BC, please visit prostatecancerbc.ca For more information on Prostate Cancer Support Canada, Prostate Cancer Foundation BC's support initiative, please visit: www.prostatecancersupport.ca The views, information, and opinions expressed in this video are those of the individuals involved and do not necessarily reflect the official policy or position of the Prostate Cancer Foundation BC or its employees. PCFBC is not responsible and does not verify for accuracy any of the information contained in the videos available for watching on this site. The primary purpose of these videos is to educate and inform, but these videos do not constitute, or replace, medical or other professional advice.

This video is a recording of a May 2022 Vancouver Prostate Cancer Support Group meeting. Visit prostatecancersupport.ca/calendar/ to join a support group meeting near you. Edmond Kwan, MD, PhD is a UBC Postdoctoral Fellow in the Urologic Sciences Department, working at the Vancouver Prostate Centre. Edmond received his M.D. in 2009 and completed his Medical Oncology Training in Melbourne, Australia in 2017 with a strong interest in the care of patients with genitourinary cancers. He completed his Ph.D. at Monash University in July 2020 focusing on whole blood transcriptomics to identify biomarkers in advanced prostate cancer. His studies were supported by a scholarship from the National Health and Medical Research Council. During his Ph.D., he was actively involved in clinical research as a Principal Investigator and led various local and international clinical trials. In July 2021, supported by a UBC Killam Fellowship, he joined the Wyatt Lab at the Vancouver Prostate Centre to systemically study the genomic landscape of de novo metastatic prostate through the analysis of ctDNA and tumour tissue. --- The views, information, and opinions expressed in this video are those of the individuals involved and do not necessarily reflect the official policy or position of the Prostate Cancer Foundation BC or its employees. PCFBC is not responsible and does not verify for accuracy any of the information contained in the videos available for watching on this site. The primary purpose of these videos is to educate and inform, but these videos do not constitute, or replace, medical or other professional advice.

About Dr. Cohen: Dr. Philip Cohen is the Division Head of Nuclear Medicine at Lions Gate Hospital in Vancouver, Canada. He is the past chairman of the Diagnostic Accreditation Subcommittee for Nuclear Medicine of the British Columbia (B.C.) Medical Association and the B.C. College of Physicians, Member-at-Large of the Canadian Association of Nuclear Medicine, and Clinical Professor at the University of B.C. Dr. Cohen has numerous publications and is a member of the editorial board of the Iranian Journal of Nuclear Medicine. He is a Fellow of the Royal College of Physicians and Surgeons of Canada in Nuclear Medicine, and also of the American Board of Nuclear Medicine. Dr. Cohen is a pioneer in Nuclear Medicine in Canada and in the usage of 3-D imaging techniques to improve diagnosis of bone disease and injury in collaboration with the Medical Imaging Research Group at University of British Columbia. Dr. Cohen has been involved in clinical research trials of new radiopharmaceuticals. To that effect, he was the first recipient of a research grant from the Lions Gate Hospital Foundation, one of several peer-reviewed awards that would follow. --- The views, information, and opinions expressed in this video are those of the individuals involved and do not necessarily reflect the official policy or position of the Prostate Cancer Foundation BC or its employees. PCFBC is not responsible and does not verify for accuracy any of the information contained in the videos available for watching on this site. The primary purpose of these videos is to educate and inform, but these videos do not constitute, or replace, medical or other professional advice.

Dr. Shreyas Lingadahalli joined the Chilliwack Prostate Cancer Support Group's December 2021 support group meeting to talk about his research in finding new therapies for prostate cancer. After medical schooling (MBBS) in India for my undergraduate studies, Dr. Lingadahalli's interest in basic and applied bio-medical research motivated him to join the MS (Biology) program at Cleveland Clinic/Cleveland State University. After obtaining his Master’s, he briefly worked as a senior research fellow in India before moving to Macau for his PhD under the supervision of Prof. Edwin Cheung. For his doctoral thesis, Dr. Lingadahalli worked on characterizing novel co-regulatory factors of AR-transcriptional complex in Prostate cancer. After completing his PhD in 2018, he moved to Vancouver Prostate Centre to join Dr. Nathan Lack’s lab for his postdoctoral training. While his work there is still aimed towards understanding the AR-mediated transcriptional regulation, he is currently focusing on defining an AR-enhancer and how mutations in these regions can affect prostate cancer. --- The views, information, and opinions expressed in this video are those of the individuals involved and do not necessarily reflect the official policy or position of the Prostate Cancer Foundation BC or its employees. PCFBC is not responsible and does not verify for accuracy any of the information contained in the videos available for watching on this site. The primary purpose of these videos is to educate and inform, but these videos do not constitute, or replace, medical or other professional advice.

In honour of Prostate Cancer Awareness Month, Dr. Phil Cohen, MD, FRCP(C), ABNM, joined our Coast to Coast Prostate Cancer Support Group Meeting as part of our Prostate Cancer Awareness Speaker Series. --- About Dr. Cohen: Dr. Philip Cohen is the Division Head of Nuclear Medicine at Lions Gate Hospital in Vancouver, Canada. He is the past chairman of the Diagnostic Accreditation Subcommittee for Nuclear Medicine of the British Columbia (B.C.) Medical Association and the B.C. College of Physicians, Member-at-Large of the Canadian Association of Nuclear Medicine, and Clinical Professor at the University of B.C. Dr Cohan has numerous publications and is a member of the editorial board of the Iranian Journal of Nuclear Medicine. He is a Fellow of the Royal College of Physicians and Surgeons of Canada in Nuclear Medicine, and also of the American Board of Nuclear Medicine. Dr. Cohen is a pioneer in Nuclear Medicine in Canada and in the usage of 3-D imaging techniques to improve diagnosis of bone disease and injury in collaboration with the Medical Imaging Research Group at University of British Columbia. Dr Cohen has been involved in clinical research trials of new radiopharmaceuticals. To that effect, he was the first recipient of a research grant from the Lions Gate Hospital Foundation, one of several peer-reviewed awards that would follow. --- The views, information, and opinions expressed in this video are those of the individuals involved and do not necessarily reflect the official policy or position of the Prostate Cancer Foundation BC or its employees. PCFBC is not responsible and does not verify for accuracy any of the information contained in the videos available for watching on this site. The primary purpose of these videos is to educate and inform, but these videos do not constitute, or replace, medical or other professional advice.

In honour of Prostate Cancer Awareness Month, Dr. Abby Collier spoke at our Prostate Cancer Awareness Month 2021 Speaker Series. Prostate cancer (PCa) affects Canadian citizens widely and is one of the most common cancers diagnosed in either genders. As time has progressed we have become better at diagnosing and treating PCa. However scientific and medical efforts continue to push the boundaries of diagnosis and therapy. In this presentation Dr Collier will present some of the newly approved diagnostics and therapeutics for PCa, including providing a broad overview of how these fields are developing from a research and clinical trial perspective. About Dr. Collier: Originally from New Zealand, Dr. Collier holds both a BSc and PhD in pharmacology from the University of Auckland. After a postdoctoral fellowship with Professor Chris Pritsos at the University of Nevada, Dr. Collier was an assistant professor, then associate professor at the University of Hawaii Medical School. A member of the Faculty of Pharmaceutical Sciences at UBC since 2013, Dr. Collier is professor of Drug Metabolism and Pharmacokinetics, teaches pharmacology to undergraduate, graduate, pharmacy and medical students, maintains an active and well-funded research lab and directs the new undergraduate BPSc degree program. Dr. Collier's sub-specialty is drug metabolism and pharmacokinetics. She is the winner of the 2021 Center for Alternatives to Animal Testing (CAAT) Award (biennial, world-wide) in recognition of her scientific research leading the field in modeling and simulation “to reduce, refine and replace animal use”. She uses a combination of laboratory work and computer modeling to improve drug/chemical safety and efficacy. Along with her collaborators, she also performs research and publishes regularly in the fields of human and environmental toxicology and endocrinology, including prostate cancer. --- The views, information, and opinions expressed in this video are those of the individuals involved and do not necessarily reflect the official policy or position of the Prostate Cancer Foundation BC or its employees. PCFBC is not responsible and does not verify for accuracy any of the information contained in the videos available for watching on this site. The primary purpose of these videos is to educate and inform, but these videos do not constitute, or replace, medical or other professional advice.